Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pfizer Inc NYS:PFE.N, US7170811035

  • 50,505 28 jun 2022 20:13
  • -1,375 (-2,65%) Dagrange 50,410 - 51,970
  • 8.562.546 Gem. (3M) 24,7M

Forum Pfizer geopend

324 Posts
Pagina: «« 1 2 3 4 5 6 ... 17 »» | Laatste | Omlaag ↓
  1. elpapa 20 januari 2021 22:51
    quote:

    Prijsman schreef op 20 januari 2021 18:36:

    Prijs / koers wordt mogelijk in toom gehouden.

    Zie hier aandeelhouders in Pfizer. Weinig freefloat / daghandel i.t.t. uitstaande aandelen. Pfizer betaalt goed dividend uit op een constante basis (ook t.t.v. Covid-19).

    coin-group.com/top-10-shareholders-of...
    money.cnn.com/quote/shareholders/shar...
    @prijsman. Waarom zouden ze dat doen?
  2. StilleWillem 21 januari 2021 13:54
    Covid-19 medicine: First patient treated in Leiden company's clinical trial
    Pharming, a biotechnology company based in Leiden, has launched its clinical trial for a medicine that could be effective in treating Covid-19, the respiratory disease caused by coronavirus SARS-CoV-2. The first of 150 patients has started treatment with Ruconest, the company announced on Monday.

    The medication is being tested on patients who develop severe pneumonia as a result of the coronavirus disease. "Systemic hyperinflammation is a hallmark of more severe stages of COVID-19 leading to acute respiratory distress syndrome, mechanical ventilation and ultimately death," the company said in a statement. It hoped that the drug would dampen an out of control immune system response, thus preventing the extent of lung damage, reduce the chance of pulmonary edema, and prevent some clots from forming.

    Pharming is working with the University Hospital Basel in Switzerland for this clinical trial. The first patient treated in this trial is also located in Basel.

    The company launched this expanded trial after a small experiment with five patients had "encouraging results" in April. Four of the five seriously ill patients' fever disappeared within 48 hours of treatment, and they were released from the hospital as fully recovered a short time later.

    The fifth patient had to be admitted to intensive care to be intubated, but also went on to a full recovery, the pharmaceutical firm said.

    Pharming said a successful clinical trial with Covid-19 patients could also lead to tests on patients with other diseases linked to hyperinflammatory syndrome and ultimately result in severe respiratory problems and organ failure complications.

    Ruconest is an anti-inflammatory agent that predates the coronavirus crisis. It was developed to treat hereditary angioedema - acute inflammatory attacks that cause sudden swelling which can be very painful, or even fatal.
  3. StilleWillem 21 januari 2021 13:55
    quote:

    Willem Endstra schreef op 21 januari 2021 13:54:

    Covid-19 medicine: First patient treated in Leiden company's clinical trial
    Pharming, a biotechnology company based in Leiden, has launched its clinical trial for a medicine that could be effective in treating Covid-19, the respiratory disease caused by coronavirus SARS-CoV-2. The first of 150 patients has started treatment with Ruconest, the company announced on Monday.

    The medication is being tested on patients who develop severe pneumonia as a result of the coronavirus disease. "Systemic hyperinflammation is a hallmark of more severe stages of COVID-19 leading to acute respiratory distress syndrome, mechanical ventilation and ultimately death," the company said in a statement. It hoped that the drug would dampen an out of control immune system response, thus preventing the extent of lung damage, reduce the chance of pulmonary edema, and prevent some clots from forming.

    Pharming is working with the University Hospital Basel in Switzerland for this clinical trial. The first patient treated in this trial is also located in Basel.

    The company launched this expanded trial after a small experiment with five patients had "encouraging results" in April. Four of the five seriously ill patients' fever disappeared within 48 hours of treatment, and they were released from the hospital as fully recovered a short time later.

    The fifth patient had to be admitted to intensive care to be intubated, but also went on to a full recovery, the pharmaceutical firm said.

    Pharming said a successful clinical trial with Covid-19 patients could also lead to tests on patients with other diseases linked to hyperinflammatory syndrome and ultimately result in severe respiratory problems and organ failure complications.

    Ruconest is an anti-inflammatory agent that predates the coronavirus crisis. It was developed to treat hereditary angioedema - acute inflammatory attacks that cause sudden swelling which can be very painful, or even fatal.
    Heeft verder niets met een vaccin te maken; alleen een e.v. ontlasting voor de IC omdat mensen "minder" ziek worden
  4. elpapa 25 januari 2021 22:28
    quote:

    Rhuno schreef op 25 januari 2021 22:08:

    EUROPEAN COMMISSION APPROVES BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Not intended for UK-based media
    Goed nieuws, hoewel ik zeer benieuwd naar wat de koers morgen gaat doen na afvallen Astrazeneca voor 65 plussers, want zo ziet het er wel naar uit.
  5. Tukkie 27 januari 2021 19:21
    Bedankt voor de reactie en dat idee had ik ook maar het blijft toch gek hoor.
    We kunnen dus verwachten dat komende weken het aandeel niet zal stijgen. Immers zouden die mensen hun slag dan wel slaan alvorens het dividend. Een mooie knal omhoog zie ik vandaag echter niet meer gebeuren. Naar mijns inziens moet dit aandelen gewoon op 40+ staan.
324 Posts
Pagina: «« 1 2 3 4 5 6 ... 17 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pfizer Inc Meer »

Koers 50,505   Verschil -1,38 (-2,65%)
Laag 50,410   Volume 8.562.546
Hoog 51,970   Gem. Volume 24.677.919
28 jun 2022 20:13
Premium

Pfizer: cijfers top, koers flop

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links